JP Morgan 2024 – Sam Deutsch
R&D
In another lightning round JP Morgan interview, editor-in-chief Jonah Comstock caught up with Sam Deutsch, CEO of Nutcracker Therapeutics, to talk briefly about the company’s lead asset for cervical dysplasia and cervical cancer and its aspirations towards an end-to-end mRNA therapeutics platform.
They discuss the potential of mRNA in combining vaccines and immunomodulators to help the body fight viruses. Later in the interview, they touch on how Nutcracker is leveraging artificial intelligence for protein discovery, and Deutsch shares his optimism about the 2024 market outlook.
Check out the brief interview from Day One of the show below.
